Search the Newsreel

Sanofi (ENXTPA:SAN) Ends Amlitelimab Development For Atopic Dermatitis After Pipeline Review

Sanofi has halted the development of amlitelimab for atopic dermatitis after a pipeline review indicated no significant improvement over existing treatments. This decision removes a key immunology asset from its portfolio and raises questions for investors regarding the reallocation of research capital. The market …

Is Sanofi (ENXTPA:SAN) Cheap On Impairments And A €1b Buyback?

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. Sanofi (ENXTPA:SAN) drew fresh investor attention after reporting €1,031 million of intangible asset impairments for Q2 2026, along with completing a €1,009 million …

Sanofi to ‘rebuild trust’ with Regeneron; Apnimed adds to string of ‘upsized’ biotech IPOs

Sanofi's new CEO, Belén Garijo, aims to strengthen the company's partnership with Regeneron, expanding their alliance and increasing transparency. This comes as Sanofi prepares for Dupixent's patent cliff by focusing on business development and M&A. Separately, Apnimed's IPO surpassed expectations, becoming the 15th "upsized" …

Sanofi’s New CEO Highlights Pipeline Prioritization

Sanofi's new CEO, Belén Garijo, has initiated an accelerated transformation roadmap focused on commercial strengths and R&D pipeline improvements. The company aims to diversify its portfolio and reduce reliance on top-selling Dupixent by prioritizing new product growth and strategically assessing its pipeline, including discontinuing …

Sanofi Shares Slide After CEO Signals Challenges to Fill Drug Pipeline

Sanofi's shares dropped sharply after its new CEO, Belen Garijo, admitted the company faces challenges in filling its drug pipeline, necessitating increased spending and potential deals. Garijo announced a revamp of the research-and-development operations and an intention to intensify dealmaking to improve growth prospects. …

Sanofi CEO ‘looking deeply’ at pipeline as clearout continues

Sanofi's new CEO, Belén Garijo, is undertaking a rigorous assessment of the company's late-stage pipeline, leading to the discontinuation of several previously touted drug candidates. Her strategy focuses on investing where science is strongest and unmet medical needs are greatest, while also considering acquisitions …

Communiqué de presse : Rapport financier semestriel 2026 de Sanofi

Rapport financier semestriel 2026 de Sanofi Paris, le 30 juillet 2026. Sanofi annonce aujourd’hui avoir mis à la disposition du public et déposé auprès de l’Autorité des marchés financiers (AMF) son rapport financier semestriel au 30 juin 2026. Le rapport financier semestriel peut être …

Sanofi drops two more programmes in R&D clear-out

Sanofi is discontinuing the development of two more R&D programs, anti-IL33 antibody itepekimab and TNF inhibitor balinatunfib, as part of a significant R&D clear-out under new CEO Belén Garijo. This follows the recent termination of amlitelimab for atopic dermatitis, marking a substantial shift in …

Sanofi Q2 Earnings Call Highlights

Key Points Interested in Sanofi? Here are five stocks we like better. Sanofi raised its 2026 outlook after second-quarter sales rose 17.8% to €11.6 billion and business EPS increased 33.3%, driven by Dupixent, new medicines and cost discipline. Dupixent quarterly sales surpassed €5 billion, …

Sanofi’s new CEO wants more ‘realistic view’ of Phase 3 go/no-go decisions

Sanofi's new CEO, Belén Garijo, is implementing a more rigorous approach to pipeline prioritization and Phase 3 go/no-go decisions, focusing on assets with strong scientific merit and long-term value. This strategy follows the discontinuation of several programs, including most amlitelimab trials, and aims to …

Regeneron beats quarterly estimates on eczema drug strength, shares rise

July 30 (Reuters) - Regeneron on Thursday beat Wall Street estimates for second-quarter revenue and profit, helped ‌by strong demand for its eczema drug Dupixent ‌and a high-dose version of its eye drug Eylea. Shares rose nearly ​5% before the bell. Here are the …

Earnings call transcript: Sanofi beats Q2 2026 estimates but stock falls premarket

Sanofi relève ses prévisions annuelles malgré un repli du titre

« Notre chiffre d’affaires devrait progresser d’environ 10 % en 2026 », Belén Garijo, la nouvelle dirigeante de Sanofi revoit à la hausse les prévisions du groupe et poursuit la revue du pipeline

Sanofi: Operatives Ergebnis im Q2 und Umsatz steigen; Umsatzprognose für 2026 angehoben

Sanofi (Nasdaq: SNY) lifts H1 2026 sales but books large amlitelimab hit

Sanofi Beats on Q2 Earnings & Sales, Stock Down on Pipeline Setbacks

Sanofi ADR earnings beat by $1.30, revenue topped estimates

Sanofi Q2 Net Profit Plunges, Business Profit Climbs On Strong Sales; Lifts FY26 Outlook

(RTTNews) - French drug major Sanofi SA (SNY, SNYNF, SAN.PA) reported Thursday sharply lower net profit in its second quarter, while business earnings climbed from last year with strong sales growth. Further, the firm upgraded its fiscal 2026 outlook. For fiscal 2026, the pharmaceutical …

Sanofi drug pipeline worries, Dupixent dependence shake shares

Sanofi's shares dropped 8% despite raising its full-year sales forecast due to strong Dupixent demand, as investors were concerned about pipeline cuts and the company's reliance on the blockbuster drug. The drugmaker scrapped the development of two treatments and announced a strategic review of …

Press Release: Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded

Sanofi Winthrop Industrie Q2 2026: double-digit sales growth and strong business EPS growth; 2026 guidance upgraded July 30, 2026 Q2 sales growth of 17.8% at CER1 and business earnings per share (EPS)2 of €2.09 Pharma launches sales increased by 48.3%, reaching €1.3 billion, driven …

Sanofi halts amlitelimab trials, preps Q2 2026 earnings amid AI drug discovery push

Sanofi is preparing to report its Q2 2026 earnings, with expected EPS of $1.10 and revenue of $12.41 billion. The company has ceased clinical development of amlitelimab for atopic dermatitis, indicating a shift in its drug pipeline. Sanofi is also intensifying its focus on …

Sanoma Oyj (STU:SNQB) Q2 2026 Earnings Call Highlights: Strong Learning Segment Growth Amidst ...

This article first appeared on GuruFocus. Net Sales in Learning: Growth driven by learning material sales in the Netherlands and continued growth in Poland. Advertising Impact: Adverse impact on Media Finland's net sales. Sales Phasing: Approximately $15 million moved from late June to early …

Sanofi Korea, postpartum care group renew MOU to strengthen infection prevention

Sanofi Korea and the Korea Postpartum Association have renewed their Memorandum of Understanding (MOU) to enhance cooperation in infection prevention and management for mothers and newborns. This extension builds upon their initial 2023 agreement, under which they've conducted educational programs and awareness campaigns, including …

The Smartest Dividend Stock to Buy With $1,000 Right Now (Spoiler: It Yields 5.6%.)

Key Points Sanofi is growing well, thanks in large part to its drug Dupixent. It has more drugs in development, some of which could turn into big sellers. Its stock is appealingly priced, too.10 stocks we like better than Sanofi › If you've got …

Sanofi and Servier execs talk oncology: Pitches, Europe's position, and China's advantage

Executives from Sanofi and Servier discussed the evolving oncology licensing landscape, highlighting divergent approaches to assessing potential partnerships and the increasing competitive threat from China. They emphasized the need for European biotech companies to increase their speed and competitiveness, while also leveraging their strengths …

Sanofi (SNY) discloses $534M portfolio across 10 positions in latest 13F

Sanofi (SNY) has filed its latest 13F Holdings Report, revealing a U.S. equity portfolio valued at $534,041,662 across 10 distinct positions. The report confirms Sanofi as the sole institutional investment manager for these holdings, with the filing signed by Alexandra Roger, Head of Legal …

SANOFICONR: Q2 2026 revenue up 7% and net profit at ₹919 million, driven by domestic sales growth

Sanofi zieht Stecker bei Amlitelimab – Aktie rutscht, Prognose stabil

Sanofi Announces Executive Leadership Reshuffle

Sanofi has announced a significant reshuffle of its Executive Committee, integrating senior figures from across its commercial, research, and global divisions to support its next phase of growth starting September 1, 2026. Belén Garijo, CEO, emphasized that the updated leadership team will focus on …

Press Release: Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews

Sanofi announced it will not submit amlitelimab for global regulatory reviews in moderate-to-severe atopic dermatitis, discontinuing its clinical development for this indication. The decision follows a strategic assessment where the drug, despite some positive results in a long-term extension study, was deemed not to …

Sanofi halts development of troubled immune drug in eczema

Sanofi has halted the development of amlitelimab, an experimental eczema drug it once considered a potential successor to Dupixent, due to mixed late-stage study results and safety concerns. This decision follows similar setbacks for other OX40L-targeting antibodies and raises questions about Sanofi's research pipeline, …

Sanofi abandons plan to seek approval for eczema drug from $1.1B Kymab buyout

Sanofi has decided to abandon its plans to seek approval for amlitelimab, an eczema drug acquired through its $1.1 billion Kymab buyout, for atopic dermatitis. The company stated that the drug would not offer a "meaningful improvement" over existing treatments, despite previous phase 3 …

Sanofi to Drop Eczema Drug Amid Review of Pipeline Under New CEO

Sanofi has announced it will not seek regulatory approval for its eczema drug, amlitelimab, after data review indicated it doesn't support further development. This decision comes as the French pharmaceutical company undergoes a pipeline review under its new chief executive. While the eczema application …

Sanofi’s $1.4B Kymab bet falters again as atopic dermatitis trials scrapped

Sanofi has scrapped most of its ongoing trials for amlitelimab, an autoimmune asset acquired from Kymab, in atopic dermatitis following its failure to significantly improve over the standard of care in Phase 3 studies. This decision, part of a strategic pipeline assessment, comes despite …

Sanofi abandons eczema drug approval efforts in another blow to OX40 class

Sanofi has decided to discontinue the development of its immunology therapy, amlitelimab, for atopic dermatitis (AD), citing a lack of meaningful differentiation from existing treatments. This decision is a setback for Sanofi, which had hoped amlitelimab would succeed its blockbuster drug Dupixent, and further …